2-Deoxy-D-glucose: Targeting Tumor Immunometabolism and Viral Replication

Introduction

The rewiring of cellular metabolism stands at the frontier of modern oncology and virology research. Among a new generation of metabolic modulators, 2-Deoxy-D-glucose (2-DG) has emerged as a foundational tool for dissecting glycolytic flux, disrupting ATP synthesis, and inducing metabolic oxidative stress. While existing articles have detailed the strategic and translational opportunities of glycolysis inhibition in cancer and virus studies (see this strategic review), and highlighted 2-DG’s cytotoxicity in classic tumor models (see this focused overview), a comprehensive exploration of how 2-DG interfaces with emerging concepts in tumor immunometabolic reprogramming and macrophage biology remains lacking. This article addresses that gap by synthesizing recent mechanistic discoveries with practical insights into how 2-DG can reshape the tumor microenvironment, modulate immune cell fate, and suppress viral replication.

Mechanism of Action of 2-Deoxy-D-glucose (2-DG)

Glycolysis Inhibition and ATP Synthesis Disruption

2-Deoxy-D-glucose (2-DG) is a structural analog of D-glucose in which the hydroxyl group at the C-2 position is replaced with hydrogen. This subtle alteration is sufficient to transform 2-DG into a potent glycolysis inhibitor. Upon cellular uptake via glucose transporters, 2-DG is phosphorylated by hexokinase to 2-DG-6-phosphate, but this metabolite cannot proceed through phosphoglucose isomerase. The result is accumulation of a metabolic dead-end, suppression of glycolytic flux, and a marked reduction in ATP synthesis.

This bioenergetic disruption triggers a cascade of downstream effects: cellular energy stress, activation of AMP-activated protein kinase (AMPK), and induction of metabolic oxidative stress. In cancer cells, which often display a heightened reliance on aerobic glycolysis (the Warburg effect), 2-DG’s interference with glucose metabolism translates to cytostatic and cytotoxic outcomes—particularly within metabolically demanding tumor contexts such as KIT-positive gastrointestinal stromal tumors (GISTs) and non-small cell lung cancer (NSCLC).

Metabolic Oxidative Stress Inducer

Beyond ATP depletion, 2-DG’s capacity to induce metabolic oxidative stress is of special interest. By impairing glycolysis, 2-DG increases the cellular NAD+/NADH ratio and elevates reactive oxygen species (ROS) levels. This pro-oxidant environment exacerbates cellular damage, particularly in rapidly proliferating tumor cells and virally infected cells whose metabolic plasticity is compromised.

Unique Insights into Tumor Immunometabolism: Integration of Macrophage Reprogramming

Linking 2-DG to Tumor-Associated Macrophage (TAM) Biology

Conventional perspectives on 2-DG focus on its direct cytotoxic effects. However, recent research has illuminated a subtler, system-level impact: the metabolic education of immune cells within the tumor microenvironment (TME). A pivotal study by Xiao et al. (2024, Immunity) revealed that metabolic reprogramming of tumor-associated macrophages (TAMs)—specifically via the lysosomal accumulation of 25-hydroxycholesterol (25HC)—activates the AMPKα pathway, shifting macrophages toward an immunosuppressive (M2-like) phenotype. This process hinges on a cascade involving the GPR155-mTORC1 complex and STAT6 phosphorylation, culminating in increased arginase (ARG1) expression and suppression of anti-tumor immunity.

2-Deoxy-D-glucose, by disrupting glycolysis and inducing metabolic stress, provides a powerful axis for modulating this TAM polarization. By lowering ATP levels and activating AMPK, 2-DG could theoretically blunt the immunosuppressive reprogramming of TAMs, potentially reversing the "cold" immune phenotype of tumors and enhancing responsiveness to immunotherapies such as anti-PD-1. Thus, 2-DG is not simply a cytotoxic agent but a tool for recalibrating the metabolic crosstalk between tumor and immune cells.

PI3K/Akt/mTOR Signaling Pathway Modulation

The PI3K/Akt/mTOR axis is a master regulator of cell growth, metabolism, and survival. 2-DG’s glycolytic blockade indirectly impacts this pathway by reducing available ATP and altering upstream signaling. Notably, the reference study found that 25HC competes with cholesterol for GPR155 binding, inhibiting mTORC1 and activating AMPKα. This mirrors the energy-sensing mechanisms engaged by 2-DG, suggesting a synergistic opportunity: combining 2-DG with agents targeting CH25H or the mTOR pathway could enhance anti-tumor immunity and metabolic stress in the TME.

Comparative Analysis: 2-DG Versus Alternative Immunometabolic Modulators

Much of the existing literature, including the "Rewiring Tumor Metabolism" review, emphasizes the translational and strategic dimensions of using 2-DG as a glycolysis inhibitor. While these articles highlight its role in metabolic pathway modulation and sensitization to chemotherapy, they do not fully explore 2-DG’s intersection with immune cell metabolic programming and the latest immunometabolic checkpoints.

In contrast, this article situates 2-DG at the crux of tumor immunometabolism, bridging metabolic inhibition with the dynamic reprogramming of TAMs, as recently elucidated by Xiao et al. (2024). This perspective is distinct from prior content, offering actionable hypotheses for leveraging 2-DG in combination with immunotherapies and metabolic checkpoint inhibitors.

Experimental Benchmarks: KIT-Positive GISTs and NSCLC

Empirical evidence underscores the efficacy of 2-DG in KIT-positive GIST cell lines, with IC₅₀ values of 0.5 μM (GIST882) and 2.5 μM (GIST430), and in combination with chemotherapeutics such as Adriamycin and Paclitaxel in NSCLC models. Notably, 2-DG’s cytotoxicity is potentiated in metabolic stress contexts—settings where immune modulation may further tip the balance toward tumor eradication.

Advanced Applications: 2-DG in Viral Replication Inhibition and Beyond

Inhibition of Viral Protein Translation

Beyond oncology, 2-DG has demonstrated robust activity as a viral replication inhibitor. By disrupting the glycolytic supply of biosynthetic precursors and ATP, 2-DG impairs the translation of viral proteins during the early stages of infection. For example, it has been shown to block porcine epidemic diarrhea virus (PEDV) replication and gene expression in Vero cells. This positions 2-DG as a versatile metabolic pathway research tool in virology, with potential for broad-spectrum antiviral strategies—particularly where viruses rely on host cell glycolysis for replication.

Synergy with Immunometabolic Checkpoints

The interplay between metabolic inhibitors and immune checkpoints is a fast-evolving field. As shown in the reference study, targeting CH25H can convert immunologically "cold" tumors into "hot" ones, enhancing T cell infiltration and synergy with anti-PD-1 therapy. Integrating 2-DG into such strategies could further disrupt the metabolic support for immunosuppressive macrophages, amplifying anti-tumor responses and offering new avenues for combination therapy in refractory cancers.

Practical Considerations: Solubility, Storage, and Experimental Design

Effective use of 2-Deoxy-D-glucose (2-DG) hinges on its chemical and biophysical properties. The compound is highly soluble in water (≥105 mg/mL), moderately soluble in DMSO (≥8.2 mg/mL), and requires warming and sonication for ethanol solubility (≥2.37 mg/mL). For experimental applications, it is recommended to prepare fresh solutions and store aliquots at -20°C, avoiding prolonged storage of working stocks to preserve activity. Typical in vitro treatment concentrations range from 5–10 mM for 24-hour exposures, though lower concentrations may be effective in sensitive cell types such as KIT-positive GISTs.

Distinctive Value: Integrating 2-DG into Next-Generation Research Paradigms

While prior articles have established the value of 2-DG as a powerful glycolysis inhibitor and a sensitizer to chemotherapy, this article uniquely synthesizes the latest advances in immunometabolic reprogramming to position 2-DG as a platform for engineering the tumor-immune interface. By understanding and manipulating the metabolic dependencies of both cancer and immune cells, researchers can design more effective, targeted, and durable therapeutic strategies.

For those seeking to translate these insights into practice, 2-Deoxy-D-glucose (2-DG) (SKU: B1027) offers a robust and validated reagent for probing glycolytic inhibition, metabolic oxidative stress induction, and modulation of immune cell fate in both cancer and viral infection models.

Conclusion and Future Outlook

2-Deoxy-D-glucose is redefining the landscape of metabolic pathway research—no longer viewed solely as a glycolysis inhibitor, but as a strategic lever for immunometabolic reprogramming. By integrating the latest findings on TAM education, AMPK/mTOR/STAT6 signaling, and metabolic checkpoint modulation (as highlighted in the seminal Xiao et al. study), this article provides a blueprint for deploying 2-DG in next-generation research and therapeutic paradigms.

As the field advances, combining 2-DG with agents targeting CH25H, mTOR, or immune checkpoints promises to unlock new synergies against hard-to-treat cancers and viral infections. Researchers are encouraged to exploit 2-DG’s multifaceted properties—glycolysis inhibition, ATP synthesis disruption, metabolic oxidative stress induction, and immune cell reprogramming—to illuminate the metabolic vulnerabilities of disease and chart a path toward more effective interventions.